CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Common Stock	Additional Paid in Capital	Deficit Accumulated	Non-Controlling interest	Total
Balance at Dec. 31, 2012	$ 7	$ 133,878	$ (109,053)		$ 24,832
Balance (in shares) at Dec. 31, 2012	66,621,832
Increase (Decrease) in Stockholders' Equity
Common stock issued via registered direct offering	$ 2	94,732			94,734
Common stock issued via registered direct offering (in shares)	17,133,093
Fees and expenses related to controlled equity sales		(5,623)			(5,623)
Cancellation of unregistered shares owned by former controlling shareholder (Callisto)	$ (2)	2
Cancellation of unregistered shares owned by former controlling shareholder (Callisto) (in shares)	(22,294,976)
Common stock issued to former Callisto shareholders	$ 3	(3)
Common stock issued to former Callisto shareholders (in shares)	28,605,379
Fair value of warrants reclassified to additional paid in capital		3,575			3,575
Recapitalization of Synergy		(4,904)			(4,904)
Common stock issued in connection with exercise of stock options		119			119
Common stock issued in connection with exercise of stock options (in shares)	61,787
Common stock issued for services rendered		250			250
Common stock issued for services rendered (in shares)	55,000
Stock based compensation expense		4,489			4,489
Net loss for the period			(62,124)		(62,124)
Balance at Dec. 31, 2013	$ 10	226,515	(171,177)		55,348
Balance (in shares) at Dec. 31, 2013	90,182,115
Increase (Decrease) in Stockholders' Equity
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement	$ 1	30,699			30,700
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement (in shares)	6,417,650
Fees and expenses related to controlled equity sales		(846)			(846)
Fees and expenses associated with ContraVir Private Placement		(15)			(15)
Common stock issued in connection with exercise of stock options		36			36
Common stock issued in connection with exercise of stock options (in shares)	9,999
Stock based compensation expense		4,722			4,722
Private placement of ContraVir common stock		3,224			3,224
Fair value of ContraVir warrants issued in connection with private placement		(880)			(880)
Noncontrolling interest of ContraVir				$ (1,622)	(1,622)
Distribution of ContraVir common stock to Synergy shareholders		(1,740)			(1,740)
Elimination of noncontrolling interest of ContraVir upon distribution				$ 1,622	1,622
Net loss for the period			(95,708)		(95,708)
Balance at Dec. 31, 2014	$ 11	261,715	(266,885)		$ (5,159)
Balance (in shares) at Dec. 31, 2014	96,609,764				96,609,764
Increase (Decrease) in Stockholders' Equity
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement		14,672			$ 14,672
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement (in shares)	3,435,998
Fees and expenses related to controlled equity sales		(404)			(404)
Common stock issued in connection with exercise of stock options		1,142			1,142
Common stock issued in connection with exercise of stock options (in shares)	269,720
Change in fair value of warrants due to expiration of certain warrants		244			244
Stock based compensation expense		9,724			9,724
Shares issued in connection with conversion of Senior Convertible Debentures		40,989			40,989
Shares issued in connection with conversion of Senior Convertible Debentures (in shares)	13,179,712
Common stock issued in connection with exercise of warrants		1,012			1,012
Common stock issued in connection with exercise of warrants (in shares)	189,412
Stock issues in exchange for certain intellectual property		67			67
Stock issues in exchange for certain intellectual property (in shares)	10,000
Net loss for the period			(117,500)		(117,500)
Balance at Dec. 31, 2015	$ 11	$ 329,161	$ (384,385)		$ (55,213)
Balance (in shares) at Dec. 31, 2015	113,694,606				113,694,606